The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer.
 
Jonathan W. Goldman
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb; Genentech; Lilly; Pfizer
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Amy Lauren Cummings
Consulting or Advisory Role - OncLive/MJH Life Sciences; Tempus
Research Funding - Amgen Foundation; Genentech (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for bioinformatics approach to identification of motif neoepitopes
 
Karo K. Arzoo
No Relationships to Disclose
 
Eddie Hong-Lung Hu
No Relationships to Disclose
 
Edward B. Garon
Consulting or Advisory Role - ABBVIE/ABBOTT; ABL Bio; Arcus Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Gilead Sciences; GlaxoSmithKline; ipsen; Lilly; Merck; Natera; Novartis; Personalis; Sanofi/Regeneron; Seagan; Shionogi; Summit Therapeutics; Xilio Therapeutics
Research Funding - ABL Bio (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Diagnosistic and therapeutic use of "Motif Neoepitopes" as defined by Cummings et al in Nature Cancer. (Inst)
Travel, Accommodations, Expenses - Novartis
 
Evangelia K. Kirimis
No Relationships to Disclose
 
Olga Olevsky
No Relationships to Disclose
 
Brian Anthony DiCarlo
No Relationships to Disclose
 
Sheldon J. Davidson
No Relationships to Disclose
 
Anita Kaul
No Relationships to Disclose
 
Zorawar Singh Noor
No Relationships to Disclose
 
Melody A. Mendenhall
No Relationships to Disclose
 
Deborah J.L. Wong
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Genentech/Roche; Regeneron; Sanofi/Aventis
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); FSTAR (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Kura Oncology (Inst); Lilly; Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst); TopAlliance BioSciences Inc (Inst)
 
Holly K.T. Huang
No Relationships to Disclose
 
Maria A Velez
No Relationships to Disclose
 
James Chauv
No Relationships to Disclose
 
Yosef Yarden
No Relationships to Disclose
 
Dennis J. Slamon
Leadership - 1200 Pharma; Biomarin; Torl Biotherapeutics
Stock and Other Ownership Interests - Amgen; Amgen; BioMarin; Merck Sharp & Dohme; Pfizer; Seagen; Vertex
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Seagen
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Biomarin; Novartis; Pfizer